Level Bio (LEVBIO) Q3 2024 earnings summary

Executive summary

• Net sales for Q3 2024 were 6,421 KSEK, up 0.1% year-over-year; operating loss improved to -884 KSEK from -2,379 KSEK.

• Result after tax was -889 KSEK, a significant improvement from -2,300 KSEK in Q3 2023.

• Cash flow improved to -621 KSEK from -2,506 KSEK year-over-year; cash at period end was 1,342 KSEK.

• Bruttomarginal remained above 50% but declined to 52% from 54% year-over-year.

• Cost reductions and improved efficiency contributed to better results despite flat sales.

Financial highlights

• Net sales: 6,421 KSEK (6,417 KSEK Q3 2023); 0.1% increase year-over-year.

• Gross margin: 52% (54% Q3 2023); gross profit 3,330 KSEK.

• Operating result: -884 KSEK (-2,379 KSEK Q3 2023); net result per share: -0.01 SEK (-0.04 SEK Q3 2023).

• Cash flow: -621 KSEK (-2,506 KSEK Q3 2023); cash and equivalents at period end: 1,342 KSEK.

• Equity ratio: 37% (68% Q3 2023); number of employees: 11 (13 Q3 2023).

Outlook and guidance

• Management expects cost reductions and new distribution agreements to support future growth.

• Cash position and receivables considered sufficient for ongoing operations; focus on achieving positive cash flow.

• Anticipates stable recurring revenue from new supplier agreements and product launches.

• Manufacturing segment expects negative growth to end within the year as customer studies conclude.